Shares of Techne Corp. (NASDAQ:TECH) traded down 0.4% during trading on Friday . The company traded as low as $114.43 and last traded at $114.73, with a volume of 87,627 shares traded. The stock had previously closed at $115.17.

A number of analysts have recently commented on the company. Zacks Investment Research cut Techne Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday. Leerink Swann reissued a “hold” rating and issued a $105.00 price target on shares of Techne Corp. in a research report on Thursday, May 5th. Finally, Janney Montgomery Scott raised Techne Corp. from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $100.00 to $118.00 in a research report on Tuesday, May 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $109.60.

The firm has a market cap of $4.29 billion and a price-to-earnings ratio of 40.99. The stock’s 50-day moving average is $111.00 and its 200-day moving average is $96.03.

Techne Corp. (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.12. During the same period in the previous year, the business earned $0.88 EPS. The firm earned $131 million during the quarter, compared to the consensus estimate of $122.65 million. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. Equities analysts anticipate that Techne Corp. will post $3.64 earnings per share for the current fiscal year.

In other news, Director Roger C. Lucas sold 500 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $100.24, for a total transaction of $50,120.00. Following the transaction, the director now directly owns 3,915 shares of the company’s stock, valued at $392,439.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $101.91, for a total transaction of $509,550.00. Following the transaction, the director now directly owns 6,559 shares in the company, valued at $668,427.69. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of TECH. Royce & Associates LLC raised its position in shares of Techne Corp. by 11.2% in the fourth quarter. Royce & Associates LLC now owns 908,569 shares of the company’s stock worth $81,771,000 after buying an additional 91,790 shares during the period. Eagle Asset Management Inc. raised its position in shares of Techne Corp. by 126.5% in the fourth quarter. Eagle Asset Management Inc. now owns 79,969 shares of the company’s stock worth $7,197,000 after buying an additional 44,658 shares during the period. TD Asset Management Inc. raised its position in shares of Techne Corp. by 306.9% in the fourth quarter. TD Asset Management Inc. now owns 29,300 shares of the company’s stock worth $2,637,000 after buying an additional 22,100 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Techne Corp. by 13.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 155,643 shares of the company’s stock worth $14,009,000 after buying an additional 18,374 shares during the period. Finally, GSA Capital Partners LLP raised its position in shares of Techne Corp. by 40.1% in the fourth quarter. GSA Capital Partners LLP now owns 39,841 shares of the company’s stock worth $3,586,000 after buying an additional 11,409 shares during the period.

Bio-Techne Corporation (Bio-Techne), formerly Techne Corporation, develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products around the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.